Literature DB >> 20638241

Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids.

Elena Kontaki1, Dimitrios T Boumpas.   

Abstract

Historically, the involvement of complement - an integral part of the innate immune response- in the pathogenesis of lupus was recognized early. Emphasis shifted quickly however to the specific immunity with scientists concentrating on the adaptive immune response (autoantigens, autoreactive T cells and autoantibodies). Similarly, the detection of interferon alpha (IFNα), another key mediator of innate immunity, in the sera of active lupus patients by Hooks and Moutsopoulos in 1979 was poorly understood and thus ignored for many years. More recently however, the realization that a) endogenous ligands ("stressors") derived from a "stressed" host can be potent inducers of inflammatory mediators, and b) a cross-talk exists between the innate and the specific immune response, has motivated investigators to take a closer look at innate immunity. To this end, studies have revealed novel inducers, sensors, mediators and effectors in the innate arm of immunity of key relevance to the pathogenesis of lupus. According to the current paradigm, nucleosomes containing nucleic acids (RNA and/or DNA) and other endogenous danger ligands that can bind to pathogen associated molecular pattern receptors are incorporated in apoptotic blebs, which in turn promote the activation of dendritic and B cells and the production of IFNα and autoantibodies, respectively. These molecules find their way to specific receptors (toll-like receptors, TLRs; the nucleotide binding and oligomerization domain receptors, NLRs; and the retinoid acid inducible gene-I-like receptors, RLRs) some of which are located intracellularly. Thus in lupus, apoptotic material is not only a source of autoantigens and molecules with adjuvant activity, but also a source of endogenous molecules that can be potent inducers of inflammatory cytokines.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638241     DOI: 10.1016/j.jaut.2010.06.009

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

Review 1.  Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR.

Authors:  Shu Man Fu; Umesh S Deshmukh; Felicia Gaskin
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

Review 2.  The therapeutic potential of epigenetics in autoimmune diseases.

Authors:  Maria De Santis; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

3.  High expression levels of microRNA-629, microRNA-525-5p and microRNA-516a-3p in paediatric systemic lupus erythematosus.

Authors:  Jia Zhu; Xiaolan Huang; Gaixiu Su; Li Wang; Fengqi Wu; Ting Zhang; Guowei Song
Journal:  Clin Rheumatol       Date:  2014-04-01       Impact factor: 2.980

Review 4.  Autoantibodies with enzymatic properties in human autoimmune diseases.

Authors:  Bharath Wootla; Sébastien Lacroix-Desmazes; Arthur E Warrington; Allan J Bieber; Srini V Kaveri; Moses Rodriguez
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

Review 5.  The autoimmune side of heart and lung diseases.

Authors:  Nancy Agmon-Levin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

6.  Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene.

Authors:  S E Löfgren; J Frostegård; L Truedsson; B A Pons-Estel; S D'Alfonso; T Witte; B R Lauwerys; E Endreffy; L Kovács; C Vasconcelos; B Martins da Silva; S V Kozyrev; M E Alarcón-Riquelme
Journal:  Genes Immun       Date:  2012-01-05       Impact factor: 2.676

7.  Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.

Authors:  Michael Murphy; Goutham Pattabiraman; Tissa T Manavalan; Andrei E Medvedev
Journal:  Eur J Immunol       Date:  2017-03-31       Impact factor: 5.532

8.  Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk.

Authors:  Jennie G Pouget; Buhm Han; Yang Wu; Emmanuel Mignot; Hanna M Ollila; Jonathan Barker; Sarah Spain; Nick Dand; Richard Trembath; Javier Martin; Maureen D Mayes; Lara Bossini-Castillo; Elena López-Isac; Ying Jin; Stephanie A Santorico; Richard A Spritz; Hakon Hakonarson; Constantin Polychronakos; Soumya Raychaudhuri; Jo Knight
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

9.  Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis.

Authors:  Svetlana Fischer; Nancy Agmon-Levin; Yinon Shapira; Bat-Sheva Porat Katz; Eduard Graell; Ricard Cervera; Ljudmila Stojanovich; Jose A Gómez Puerta; Raimon Sanmartí; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

10.  MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus.

Authors:  Yun Deng; Jian Zhao; Daisuke Sakurai; Kenneth M Kaufman; Jeffrey C Edberg; Robert P Kimberly; Diane L Kamen; Gary S Gilkeson; Chaim O Jacob; R Hal Scofield; Carl D Langefeld; Jennifer A Kelly; Rosalind Ramsey-Goldman; Michelle A Petri; John D Reveille; Luis M Vilá; Graciela S Alarcón; Timothy J Vyse; Bernardo A Pons-Estel; Barry I Freedman; Patrick M Gaffney; Kathy Moser Sivils; Judith A James; Peter K Gregersen; Juan-Manuel Anaya; Timothy B Niewold; Joan T Merrill; Lindsey A Criswell; Anne M Stevens; Susan A Boackle; Rita M Cantor; Weiling Chen; Jeniffer M Grossman; Bevra H Hahn; John B Harley; Marta E Alarcόn-Riquelme; Elizabeth E Brown; Betty P Tsao
Journal:  PLoS Genet       Date:  2013-02-28       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.